GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo

Prostate cancer is the leading malignancy and the second most common cause of cancer-related death in men. Despite high cure rates with surgery and/or radiation, 30%–40% of patients eventually develop advanced cancer. Docetaxel is one of the most effective and well established chemotherapeutic agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fayou, Chen, Xianguo, Fan, Song, Tai, Sheng, Jiang, Changqin, Zhang, Yifei, Hao, Zongyao, Zhou, Jun, Shi, Haoqiang, Zhang, Li, Liang, Chaozhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403692/
https://www.ncbi.nlm.nih.gov/pubmed/25926740
http://dx.doi.org/10.2147/OTT.S79105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403692/
https://www.ncbi.nlm.nih.gov/pubmed/25926740
http://dx.doi.org/10.2147/OTT.S79105

Ejemplares similares